It can be advanced that the new NHE1 inhibitors show a great promise as a new and selective approach to the treatment of a wide array of different malignant tumours and even leukaemias and, hopefully, they will help to overcome the present impasse and flat progress in cancer treatment [291,315,316]. Here, SLC9A1 is linked to cancer.